Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 4,000 Shares of StockDefense World · 4 days ago
CRISPR Therapeutics (NASDAQ:CRSP) & Septerna (NASDAQ:SEPN) Head-To-Head SurveyDefense World · Sep 28, 2026
Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)Defense World · Sep 24, 2026
Comparing WAVE Life Sciences (NASDAQ:WVE) and Septerna (NASDAQ:SEPN)Defense World · Sep 22, 2026
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 13,300 Septerna, Inc. $SEPNDefense World · Sep 16, 2026
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 10, 2026Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.43 | -$0.29 | Beat |
| May 12, 2026 | -$0.51 | -$0.19 | Beat |
| Mar 9, 2026 | -$0.23 | -$0.24 | Miss |
| Nov 10, 2025 | $0.19 | -$0.09 | Miss |
| Aug 11, 2025 | -$0.05 | -$0.56 | Miss |
| May 15, 2025 | -$0.38 | -$0.49 | Miss |